Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663325 | 0.85 | CYP11B1 (0.41) | ADRA2CCYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL661401 | 0.85 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP19A1SMN1; SMN2TBXAS1 | |
| SCHEMBL29868527 | 0.85 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP19A1SMN1; SMN2TBXAS1 | |
| SCHEMBL29869045 | 0.81 | HTR7 (0.43) | CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL662274 | 0.81 | HTR7 (0.43) | CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL4033145 | 0.75 | TRIM24 (0.61) | SMN1; SMN2 | |
| SCHEMBL662426 | 0.74 | ALDH1A1 (0.39) | CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL29868170 | 0.74 | ALDH1A1 (0.39) | CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL661531 | 0.73 | HDAC1 (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL11526516 | 0.73 | BRD4 (0.55) | CYP11B1CYP11B2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706376-B1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-03-04 | — | — | EP | claimed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | claimed |
| JP-2007513105-A | — | — | 2007-05-24 | — | — | JP | claimed |
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | claimed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | claimed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | claimed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | claimed |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | ADRA2C 118/4885CYP11B1 2462/4885CYP11B2 1347/4885 |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | ADRA2C 634/4885CYP11B1 2146/4885CYP11B2 1419/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | ADRA2C 634/4885CYP11B1 2146/4885CYP11B2 1419/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | ADRA2C 895/4885CYP11B1 2433/4885CYP11B2 1213/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ADRA2C 293/4885CYP11B1 2780/4885CYP11B2 1685/4885 |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | ADRA2C 190/4885CYP11B1 58/4885CYP11B2 35/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | ADRA2C 116/4885CYP11B1 1952/4885CYP11B2 1027/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | ADRA2C 190/4885CYP11B1 58/4885CYP11B2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.